|
Daily Medical Update
Psoriatic arthritis
Wednesday, August 26, 2026
|
🔬 Practice-Changing Findings
Evidence from RCTs and meta-analyses published in the
last 12 months.
|
Medicine (2026) - Meta-Analysis
Key Findings
- Across 17 studies involving 5,655 patients, adalimumab improved ACR20, ACR50, and ACR70 responses versus control (RR 2.27, 3.92, and 5.75, respectively).
- Adalimumab also improved PASI75, PASI90, PASI100, PsA response criteria, enthesitis resolution, and minimal disease activity.
- Overall and serious adverse-event risks were not significantly increased, but elevated liver enzymes were identified as a potential hepatotoxicity signal.
📋 Practice Implication: Adalimumab remains an effective option for combined joint and skin disease, with liver-enzyme monitoring warranted alongside routine safety surveillance.
|
Frontiers in immunology (2025) - Meta-Analysis
Key Findings
- All evaluated IL-targeted treatment groups improved ACR20, ACR50, ACR70, and minimal disease activity outcomes versus placebo.
- Bimekizumab, secukinumab, and ixekizumab produced the strongest short-term improvements, while tildrakizumab appeared promising in subgroup analyses.
- Most safety outcomes did not differ significantly from placebo; bimekizumab 160 mg every four weeks increased adverse events and nasopharyngitis risk.
📋 Practice Implication: When selecting an IL-targeted biologic, secukinumab or ixekizumab may offer a favorable efficacy-safety balance, whereas bimekizumab requires closer adverse-event counseling.
|
Rheumatology (Oxford, England) (2026) - Meta-Analysis
Key Findings
- In five observational studies of 2,300 patients, lack of response was comparable for cycling versus swapping strategies (risk ratio 0.99, 95% CI 0.70-1.41).
- Twelve-month retention and 24-month retention were comparable for cycling versus swapping (risk ratios 0.91 and 0.96, respectively).
- Adverse-event risk was also comparable between strategies (risk ratio 0.94, 95% CI 0.38-2.34).
📋 Practice Implication: After primary TNF-inhibitor failure, clinicians can individualize cycling versus mechanism switching according to disease domains, comorbidities, access, and patient preference rather than presumed retention superiority.
|
Rheumatology (Oxford, England) (2026) - Randomized Controlled Trial
Key Findings
- Among TNF-inhibitor inadequate responders, guselkumab produced higher week-24 dactylitis and enthesitis resolution rates than placebo (44.8%/39.7% versus 25.0%/18.8%).
- Among guselkumab-treated patients, resolution rates increased through week 48 to 67.2% for dactylitis and 55.6% for enthesitis.
- Week-24 resolution increased the odds of achieving week-48 ACR50/70, DAPSA low disease activity or remission, PASI100, and minimal or very low disease activity (odds ratios 2.88-13.38).
📋 Practice Implication: For TNF-inhibitor inadequate responders with dactylitis or enthesitis, reassessing these domains by week 24 can help identify whether guselkumab is translating into broader disease control.
|
The Lancet. Rheumatology (2025) - Randomized Controlled Trial
Key Findings
- At six months, ACR50 was achieved by 42% of patients receiving early secukinumab and 35% receiving standard care; the difference was not statistically significant (RR 1.19, 95% CI 0.75-1.88).
- By month 12, both treatment strategies produced similar clinical improvements, with approximately half of patients attaining ACR50.
- Adverse events occurred in 50% versus 53% and serious adverse events in 10% versus 8% of the early-intensive and standard-care groups, respectively; no deaths occurred.
📋 Practice Implication: For newly diagnosed, DMARD-naive PsA, a structured step-up treat-to-target pathway remains a reasonable alternative to immediate biologic-first therapy when close disease-activity monitoring and escalation are available.
|
|
💡
Summary
Across five high-significance studies, biologic therapies showed substantial efficacy across joint, skin, enthesitis, and dactylitis outcomes, while comparative evidence helped clarify sequencing after TNF-inhibitor failure. The STAMP trial found that early intensive secukinumab was not statistically superior to standard step-up care at six months, with similar clinical improvement by one year.
|
|